Pharma-Tech is an Egyptian joint stock company established in 2006.Here at Pharma-Tech we inspire for good health and better quality of life by offering a wide range of carefully selected products that will help millions of people live their lives better and healthier.we aim to touch people lives not just in Egypt but also in Middle East, Africa, and Europe. We will be involved in different therapeutic areas to help challenge the most feared diseases of our time like Osteoporosis, hyperprolactinemia, and hepatitis. At pharma-Tech we believe in the concept of “pain free hospitals” that’s why we will be offering different products in pain management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NELSON PHARMACY FINED $344,000 AND DIRECTOR $50,000 FOR PRICE-FIXING

Miragenews | June 07, 2020

news image

The Wellington High Court has ordered Prices Pharmacy 2011 Limited and a director of the company, Stuart Hebberd, to pay fines of $344,000 and $50,000 respectively, after they admitted engaging in price-fixing in breach of the Commerce Act. The Commission filed proceedings in April 2018 alleging that Prices Pharmacy 2011 Limited and its directors facilitated a price-fixing arrangement with competing Nelson pharmacies in May 2016, in breach of Part 2 of the Commerce Act. In most cases, the arrang...

Read More

PHARMACY MARKET

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

news image

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More

PHARMACY MARKET

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

news image

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

news image

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More
news image

NELSON PHARMACY FINED $344,000 AND DIRECTOR $50,000 FOR PRICE-FIXING

Miragenews | June 07, 2020

The Wellington High Court has ordered Prices Pharmacy 2011 Limited and a director of the company, Stuart Hebberd, to pay fines of $344,000 and $50,000 respectively, after they admitted engaging in price-fixing in breach of the Commerce Act. The Commission filed proceedings in April 2018 alleging that Prices Pharmacy 2011 Limited and its directors facilitated a price-fixing arrangement with competing Nelson pharmacies in May 2016, in breach of Part 2 of the Commerce Act. In most cases, the arrang...

Read More
news image

PHARMACY MARKET

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More
news image

PHARMACY MARKET

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More
news image

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us